- Jul 31 2017
Cancer Expert Joins PDS
Head and Neck Cancer and HPV Cancer Expert Joins Team of Immunology and Immuno-oncology Experts
North Brunswick, NJ—PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the appointment of Dr. Neil Gross, M.D., FACS., Professor and Director of Clinical Research in the Department of Head and Neck Surgery at MD Anderson Cancer Center, to the company’s Scientific and Clinical Advisory Board.
Dr. Gross is a surgeon-scientist with an active clinical practice focused primarily on the treatment of head and neck cancer, and has overseen a broad range of observational and therapeutic clinical trials in that area. Dr. Gross’s research efforts focus on the epidemiology of human papillomavirus (HPV) associated cancers of the head and neck, development and validation of improved prognostic tools for head and neck cancer patients, the study of the molecular basis of carcinogenesis in humans, and the application of novel molecular therapeutics in cutaneous SCCHN and transoral robotic surgery (TORS). Dr. Gross is a key opinion leader and is widely published in the field.
Dr. Gross obtained his medical degree from Oregon Health and Science University in Portland, OR. He did his clinical residency in otolaryngology-head and neck surgery at the Oregon Health and Science University, and a research fellowship in head and neck surgery at the Memorial Sloan-Kettering Cancer Center in New York, NY. Dr. Gross started his academic career as an Associate Professor in the Department of Otolaryngology and Head and Neck Surgery at the Oregon Health and Science University. He has been at MD Anderson Cancer Center since 2014.
Versamune® is a novel clinical stage, synthetic lipid-based immunotherapy platform. The Versamune®-based products which are administered by sub-cutaneous injection, have been demonstrated to facilitate superior anti-tumor efficacy due to the platform’s multi-functional mechanism of action. The platform provides potent activation of the type I interferon genes. The mechanism of action also involves effective presentation of the tumor antigens via the MHC Class I pathway. Both mechanisms together promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ T-cells. This result as well as excellent safety were confirmed in a Phase 1/2a human clinical trial. The Versamune® approach also inhibits immune-suppressive regulatory T-cells within the tumors, further facilitating the anti-tumor efficacy of the products. The Versamune® platform is now being applied to the development of multiple Phase 2b clinical-stage cancer products, including both early and late-stage cancer indications as well as combinations with other successful immune-oncology approaches such as checkpoint inhibitors.
About PDS Biotechnology
PDS Biotechnology is a private biopharmaceutical company with a growing pipeline of simpler, safer, and more effective clinical-stage immunotherapies to treat various early-stage and late-stage cancers. PDS is progressing a pipeline of immuno-oncology products to treat various cancers including, head and neck cancer, cervical cancer, prostate cancer, breast cancer etc. into phase 2 human clinical trials. This progression is based on successful demonstration of safety and strong induction of antigen-specific CD8+ T-cell responses in a recently completed phase 1/2a human clinical trial.